^
Association details:
| Biomarker: | ALK wild-type |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
Published date:
03/17/2022
Excerpt:
The study was designed to evaluate the efficacy and safety of treatment with tislelizumab plus low-dose nab-paclitaxel in patients aged ≥65 years who had metastatic NSCLC with disease progression after platinum-based chemotherapy or targeted therapy….The median PFS was significantly higher in patients with nonsquamous NSCLC with EGFR/ALK wild type (11.9 months; 95% CI, 9.3-14.5 months) than in those with EGFR/ALK variations (7.0 months; 95% CI. 3.5-10.5 months; HR, 0.56; 95% CI, 0.33-0.97; P=0.032)
Secondary therapy:
albumin-bound paclitaxel
DOI:
https://doi.org/10.3389/fonc.2022.802467
